· AIM:Totest thetherapeuticeffectsof delayed treatmentofmesenchymalstemcells(MSCs)inrecurrent experimentalautoimmuneuveitis(rEAU).
INTRODUCTION
W ithoutefficienttherapy,chronicandrecurrent autoimmuneuveitisinvolvingthechoroidandretina willresultinirreversiblevisualdisabilityandblindness causedbyretinaldamageandopticnerveatrophy.Ina majorityofcases, long-termusageof systemic corticosteroidsorcombination ofcorticosteroidsand immunosuppressantsisneeded.However,thesetreatments may leadtoawiderangeof systemicandocular complications,whichlimittheirapplicationsinseverecases thatrequiremorepowerfultherapeuticregimens [1] .Biologics, asnewlydevelopedsteroid-sparingagents,potentiallyoffera saferprofile,butdonotnecessarilyapplytoallcases becausetheytargetonlyasinglespecificmediator,and humanuveitisishighlyheterogeneous [2] [3] [4] . Theimmunosuppressiveandanti-inflammatorypropertiesof mesenchymalstemcells(MSCs)arenowverywell established [5] ,raisingthepossibilityofnewtherapiesfor autoimmunediseases(ADs),includinguveitis [6] [7] [8] [9] .MSC therapycantargetmultiplepathogenicprocessesinADs,and notissuetoxicityhasbeenfoundinMSCs [5] .Although severalpreclinicalmodelsandpilotclinicalstudiesprovidea strongimpetusfortranslatingMSCtherapytowidespread clinical use,theappropriateprotocolsfor MSC administrationstilllackrigorousstandards.Furtherdataare necessarytoevaluateandoptimizethetherapeuticregimens andestablishclearguidelinesforMSC-basedtherapies.Our previousstudiesonrecurrentexperimentalautoimmune uveitis (rEAU)ofratsdemonstratedthatasinglecourseof MSCtreatmentadministeredattheonsetofthedisease effectivelyreducedocularinflammationandfrequencyof relapses,whereasdoublecoursesoftherapyfailedto enhancethetherapeuticeffectwiththesecondtherapy appliedbeforethesecondattack [9] . However,theaboveresultscannotcompletelyguidethe complicatedclinicalsettings.Tofurtheroptimizethe therapeuticregimensofMSCtherapyinchronicand recurrentuveitis,wetestedtheefficiencyofMSCtherapy administeredatthelaterphaseofthediseaseinthepresent study.Wealsotesteddoublecoursesoftherapywiththe secondcourseappliedafteralongerinterval.Thisstudywill provideadditionalreferentialbasisforfutureclinicaltrials. MATERIALSANDMETHODS Materials MaleWistarrats(4-6wk)andfemaleLewisrats (6-8wk) wereobtainedfromVitalRiver(Beijing,China). These ratswerefedandmaintainedinspecified pathogen-freeconditionsunder12hlight/12hdarkcycles.All proceduresinvolvingratswereapprovedbytheLaboratory AnimalCareandUseCommitteeofTianjinMedical UniversityandconformedtotheARVOStatementforthe UseofAnimalsinOphthalmicandVisionResearch. Induction of Recurrent Experimental Autoimmune UveitisinLewisRats TheinductionofrEAUinLewisrats bytransferofantigen-specificTcellswasperformedas describedpreviously [5] .Theratsweresubcutaneously immunizedwith200 滋gofemulsioncontaining500 滋gof MycobacteriumtuberculosisH37Ra(Difco,Detroit,MI, USA)and50 滋gofIRBPpeptideR16(residues,1177-1191, ADGSSWEGVGVVPDV;Sangon,Shanghai,China)in incompleteFreund爷sadjuvant (Sigma-AldrichCorp.,St. Louis,MO,USA),distributedoversixspotsonthetailbase andflank.Asingle-cellsuspensionwasobtainedfromthe lymphnodesandspleensoftheratsbypassagethrougha nylonwoolcolumnat10dpost-immunization.Nonadherent cellswereidentifiedasTcells.Adherentcellswerethen incubatedoniceandirradiatedwith30Gytoserveas antigen-presentingcells(APCs).TheTcells(1伊10 7 )were stimulatedby10 滋g/mLR16with1伊 10 7 irradiatedAPCsin 2mLofRPMI-1640mediumsupplementedwith15% interleukin-2inasix-wellplateat37℃ and5%CO 2 for48h. TheTcellswerethenisolatedinLymphoprep(Robbins Scientific,MountainView,CA,USA).Toinducerecurrent uveitis,1伊 10 7 stimulatedTcellswereinjectedintravenously intooneLewisrat. IsolationandCharacterizationofMesenchymalStem Cells BonemarrowMSCswereisolatedfromtheWistar ratsasdescribedpreviously [8] .Bonemarrowsamplesfrom tibiaeandfemurswerecollectedbyflushingthediaphysis with Dulbecco'smodifiledEagle'smedium(DMEM). Collectedcellswereincubatedincompletemediacontaining DMEM/F12(Invitrogen,Carlsbad,CA,USA)and10%fetal bovineserum(Invitrogen),supplementedwith100U/mL penicillinand100 滋g/mLstreptomycin(Invitrogen)with5% CO 2 at37℃ foratleast24h.Themediumwasthenchanged andtheadherentcellswereincubatedfor8-12duntilthey reachedapproximately80%confluency.Thesecellswere thenpassaged3-5timesbeforeuse. MSCsaredefinedbytheircapacitytodifferentiateinto osteocytes,chondrocytes,andadipocytesunderappropriate conditions.TheexpressionofCD90andCD29,and thelackofhematopoieticmarkersCD34andCD45,was detectedtofurtheridentifyMSCsasdescribedpreviously [8] . [11] .Photographs ofthesuperiorandinferiorhemispheresatsixdefinedpoints wereobtainedusingacameraattachedtoalightmicroscope (OlympusBX51;Olympus,Tokyo,Japan).Thedegreeof retinaldamagewasalsoassessedbymeasuringthethickness ofboththeretinaandtheouternuclearlayer(ONL)as previouslydescribed [9] . Figure 1A-1D) ;whereaslatertherapy significantlyalleviatedtheclinicalseveritybutslightly affectedthefrequencyofrelapse (Figure1C,1D,1E 4 )for thelast20d.Double therapiesledto betterclinical evaluationduringthelast20dthansingletherapygivenat thestartofthedisease (Figure1C,1E 3 ) . Itwaspreviouslyreportedthattheprogressionofposterior diseaseisnotalwaysassociatedwiththeseverityofanterior inflammation,andinflammatorychangesintheposterior chamberandretinadegenerationarelessreadilydetectedby slim-lampbiomicroscopy [13] . .Byusingthismodel,wedemonstrated thatasinglecourseofMSCtreatmentadministeredduring theonsetofthediseasesufficedtoinhibittheprogressand relapseofthedisease [9] .However,inclinicalsettingswhere situationsareusuallymorecomplicated,notallpatientscan receivetimelyandsufficienttreatmentatthebeginningof thedisease.Therefore,despitetheobservationthatearly treatmentwithMSCsismoreeffective,itisoftherapeutic importancethatMSCswerealsoeffectivewhenadministered indevelopeddiseases. Inthisexperiment,wefoundthatalthoughearlytreatmentis advantageousoverlatertreatmentintermsofreducingthe relapseofthediseaseandprotectingretinalstructureand function,latertreatmentcanalsoeffectivelyalleviateclinical severity,decreaseinflammation,interruptdisruptionofouter retinallayers,andimproveretinalfunction.Inchronic experimentalautoimmuneencephalomyelitis(EAE)model ofmice,MSCsadministeredafterthepeakofdisease severitysignificantlyamelioratedtheclinicalcourse [14] .In recentsuccessfulclinicaltrialsofotherADs,MSCtherapies wereonlyappliedinpatientswithrefractoryinflammation, whichisdifficulttobecontrolledbycurrentlyavailable therapies.Therefore,ourresultsdonotonlyunderlinethe importanceofearlyMSCtreatmentforrecurrentandchronic uveitis,butalsofurthersupportthepracticabilityofclinical trialsonMSCtherapyforchronicrefractoryautoimmune uveitis. TheoptimaldosageandfrequencyofMSCadministration remainobscuredespitemanyrelatedclinicalandanimal experiments.Ourpreviousstudiesdemonstratedthat,for rats,onecourseofintravenousinjectionofratMSCsfor threeconsecutivedayswasneededtocontrolthedisease [7] [8] [9] , whereasoneinjectionofbothmouse-andhuman-derived MSCs was sufficientforalong-terminflammation suppressioninmice (unpublishedresults).Furthermore,we demonstratedthatsinglecourseofMSCtreatment,startedat theonsetofthedisease,sufficedtoinhibittheinflammation, whiledoubletherapies,withthesecondtherapyapplied beforethesecondattack(11dafterthefirsttherapy),didnot improvethetherapeuticbenefitinrEAUinrats [9] .Although otherstudiesreportedasimilarlastingeffectofoneMSC therapyandthefailureofsecondtherapytoprovide additionalbenefits [15] [16] ,anenhancedclinicalefficacyby multipletherapieswasalsofoundinlupusmice [17] and refractorysystemiclupuserythematosusandgraft-versushostdiseasepatients [18] [19] .Inthecurrentexperiment,we postponedthesecondtherapyuntilafterthesecondattack. Interestingly,wefoundthatdoubletherapieswithlonger intervalledtoabetterclinicalevaluation,aswellasatrend ofdecreaseinrelapseandameliorationofretinalfunction. Theseopposingresultsmightbeattributedtothedifferences indose,time,andintervalsofMSCadministrations,aswell asthedifferentclinicalconditionsoftheanimalsand patients.Previous studiesrevealedthatTcellswere arrestedattheG1phaseinthepresenceofMSCs,andthe proliferationpotentialcouldnotrecoverafterMSCs removal [20] ,whichmay explainthelong-term immunosuppressiveeffectofMSCs .However,the arrestedTcellsmighteventuallyrestoretheirproliferation ability afteracertaintime,andthesecondMSC therapyappliedatthistimemaysuppresstheirrestored effectorability.Anyway,ourdatasuggestthatdifferent regimensshouldbeplannedinclinicaltrialstoexplorethe therapeuticpotentialofMSCs. Althoughthepatternofclinicalsymptomsvariedfromcase tocase,inrEAU,thepersistentchronicintraocular inflammationleadstoprogressiveretinaldamage,especially photoreceptorloss,whichbecomesincreasinglyprominent withthetime [13] .Inourstudy,histologicalexamination revealedthatbothearlyandlaterMSCtherapiesslowed downthelossofphotoreceptorcells.Thedeteriorationof retinalstructuresinrEAUandthetherapeuticeffectofMSCs werealsoreflectedinERGresponses.Consistentwith histologicalassessment,ERGresultsdemonstratedthatboth earlyandlaterMSCtherapyeffectivelyrescuedtheretinal function,whichfurtherconfirmedthetherapeuticefficacyof MSCsinrEAU. ItisbelievedthatMSCsexertcomprehensiveimmune modulationinamultifactorialmanner [5] .Ourprevious results [7] [8] [9] revealedthat,inrEAU,MSCscouldinhibitboth Th1andTh17responses,suppressfunctionsofAPCs,and up-regulateTregcellsbyinhibitorycytokineproduction, CD73expression(unpublishedresults),andthesecretionof immunoregulatory extracellularvesicles(unpublished results).Inaddition,MSCsdemonstrateneuroprotective propertiesbyreducingoxidativestress [21] andsecreting neurotrophicfactors [22] .MSCswereproventoproducea beneficialeffect bimodalmechanisminchronicEAEby inhibitingtheimmuneresponseintheearlyphasesofthe disease,aswellasbyinducinglocalneuroregenerationin stabilizeddiseases [14] . 
